Dymon Asia Capital Singapore PTE. LTD. Decreases Stock Position in IQVIA Holdings Inc. $IQV

Dymon Asia Capital Singapore PTE. LTD. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 84.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,500 shares of the medical research company’s stock after selling 14,100 shares during the period. Dymon Asia Capital Singapore PTE. LTD.’s holdings in IQVIA were worth $564,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Eagle Rock Investment Company LLC lifted its stake in IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after acquiring an additional 11,657 shares during the period. EDENTREE ASSET MANAGEMENT Ltd bought a new stake in shares of IQVIA in the third quarter worth approximately $7,368,000. AMG National Trust Bank bought a new stake in shares of IQVIA in the third quarter worth approximately $3,713,000. Citigroup Inc. raised its holdings in shares of IQVIA by 108.2% during the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock valued at $173,830,000 after purchasing an additional 475,557 shares during the last quarter. Finally, Dana Investment Advisors Inc. lifted its position in IQVIA by 18.4% during the third quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company’s stock valued at $30,401,000 after purchasing an additional 24,854 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Evercore reaffirmed an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research note on Friday, March 6th. Royal Bank Of Canada assumed coverage on IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, Truist Financial dropped their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Stock Up 0.0%

NYSE IQV opened at $181.10 on Friday. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $30.23 billion, a P/E ratio of 22.44, a price-to-earnings-growth ratio of 1.56 and a beta of 1.21. The stock’s 50-day moving average price is $173.56 and its 200-day moving average price is $193.68.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the company posted $2.70 EPS. The firm’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its board has authorized a share repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.